<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article article-type="letter" dtd-version="1.0" specific-use="sps-1.8" xml:lang="es" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
	<front>
		<journal-meta>
			<journal-id journal-id-type="publisher-id">rac</journal-id>
			<journal-title-group>
				<journal-title>Revista argentina de cardiología</journal-title>
				<abbrev-journal-title abbrev-type="publisher">Rev Argent Cardiol</abbrev-journal-title>
			</journal-title-group>
			<issn pub-type="ppub">0034-7000</issn>
			<issn pub-type="epub">1850-3748</issn>
			<publisher>
				<publisher-name>Sociedad Argentina de Cardiología</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="doi">10.7775/rac.es.v93.i2.20887</article-id>
			<article-id pub-id-type="publisher-id">00017</article-id>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>CARTAS DE LECTORES</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Correlación de ergoespirometría con ecocardiograma en hipertensión arterial pulmonar</article-title>
				<trans-title-group xml:lang="en">
					<trans-title>Correlation of Ergospirometry with Echocardiography in Pulmonary Arterial Hypertension</trans-title>
				</trans-title-group>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-8508-4482</contrib-id>
					<name>
						<surname>SORASIO</surname>
						<given-names>GUILLERMINA</given-names>
					</name>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
					<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
					<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
					<xref ref-type="fn" rid="fn0"><sup>MTSAC</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff1">
				<label>1</label>
				<institution content-type="original"> Responsable de Insuficiencia cardíaca e Hipertensión Pulmonar del Hospital Rivadavia,</institution>
				<institution content-type="normalized">Hospital Rivadavia</institution>
				<country country="AR">Argentina</country>
			</aff>
			<aff id="aff2">
				<label>2</label>
				<institution content-type="original"> Staff de Hipertensión Pulmonar de Trinidad Ramos Mejía</institution>
				<institution content-type="normalized">Trinidad Ramos Mejía</institution>
				<country country="AR">Argentina</country>
			</aff>
			<aff id="aff3">
				<label>3</label>
				<institution content-type="original"> Staff de red de clínicas BASA salud .</institution>
				<institution content-type="normalized">red de clínicas BASA salud</institution>
				<country country="AR">Argentina</country>
				<email>guillerminasorasio@gmail.com</email>
			</aff>
			<author-notes>
				<corresp id="c1">
					<label>Dirección para correspondencia</label>: Guillermina Sorasio. Las Heras 2670. Ciudad de Buenos Aires Correo electrónico: guillerminasorasio@gmail.com</corresp>
				<fn fn-type="conflict" id="fn1">
					<label>Declaración de conflicto de intereses</label>
					<p> Los autores declaran que no tienen conflicto de intereses. (Ver formulario de conflicto de intereses en la web)</p>
				</fn>
				<fn fn-type="conflict" id="fn2">
					<label>Consideraciones éticas</label>
					<p> No aplica</p>
				</fn>
			</author-notes>
			<!--<pub-date date-type="pub" publication-format="electronic">
				<day>16</day>
				<month>05</month>
				<year>2025</year>
			</pub-date>
			<pub-date date-type="collection" publication-format="electronic">
				<season>Mar-Apr</season>
				<year>2025</year>
			</pub-date>-->
			<pub-date pub-type="epub-ppub">
				<season>Mar-Apr</season>
				<year>2025</year>
			</pub-date>
			<volume>93</volume>
			<issue>2</issue>
			<fpage>167</fpage>
			<lpage>168</lpage>
			<permissions>
				<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/" xml:lang="es">
					<license-p>Este es un artículo publicado en acceso abierto bajo una licencia Creative Commons</license-p>
				</license>
			</permissions>
			<counts>
				<fig-count count="0"/>
				<table-count count="0"/>
				<equation-count count="0"/>
				<ref-count count="5"/>
				<page-count count="2"/>
			</counts>
		</article-meta>
	</front>
	<body>
		<p>La Hipertensión arterial pulmonar (HAP) es una entidad heterogénea, crónica y progresiva que lleva a un remodelado de las arteriolas pulmonares con posterior aumento de las resistencias vasculares pulmonares (RVP) y deterioro de la función del</p>
		<p>ventrículo derecho, el principal factor predictor de mortalidad. (<xref ref-type="bibr" rid="B1">1</xref>)</p>
		<p>Es fundamental realizar una adecuada estratificación de riesgo basal y de seguimiento en estos pacientes con el objetivo de iniciar un tratamiento precoz en base a los scores de riesgo ya conocidos. (<xref ref-type="bibr" rid="B2">2</xref>)</p>
		<p>Si bien el test de caminata de 6 minutos es la técnica más accesible y sencilla para valorar capacidad funcional, presenta ciertas limitaciones como la influencia del sexo, edad, talla, peso, comorbilidades y curva de aprendizaje, entre otras. Por tal motivo la ergoespirometría o test de ejercicio cardiopulmonar (TECP) es el método ideal para determinar la limitación al ejercicio, aunque es poco accesible y costosa. (<xref ref-type="bibr" rid="B3">3</xref>)</p>
		<p>Como mencionábamos, estratificar basalmente y en seguimiento a los pacientes con HP es prioritario y el TECP, con variables como consumo de oxígeno pico (V02 pico) y el cociente entre ventilación y producción de dióxido de carbono (VE/VCO2) es una parte importante de la evaluación. (<xref ref-type="bibr" rid="B4">4</xref>)</p>
		<p>Dentro de las variables ecocardiográficas la relación entre la distancia de excursión sistólica del plano del anillo tricúspideo (TAPSE) y la presión sistólica de la arteria pulmonar (PSAP) como subrogante del acoplamiento ventrículo arterial y la reducción del índice del volumen sistólico (IVS) se han asociado a mal pronóstico en HAP.</p>
		<p>La asociación pronostica entre las variables del TECP, principalmente la relación VE/VCO2 y el V02, y las del ecocardiograma (TAPSE/PSAP) no está bien establecida.</p>
		<p>El estudio de D’ Amelio y colaboradores evaluó la capacidad predictiva de parámetros ecocardiográficos de función del ventrículo derecho en relación con la capacidad de ejercicio y comparó las variables del TECP con el ecocardiograma. Se incluyeron 7 pacientes, en mayor medida con HAP e hipertensión pulmonar tromboembólica crónica (HPTEC). Se observó una correlación estadísticamente significativa en la regresión lineal entre la relación TAPSE/PSAP y V02 pico. Si bien el número de pacientes es limitado para tomar decisiones, es una hipótesis interesante a la hora de poder correlacionar el ecocardiograma, que es más accesible, con el TECP y así poder determinar la capacidad funcional de los pacientes con HAP, un parámetro</p>
		<p>pronóstico de importancia. El resto de las variables del TECP (como la pendiente VE/VCO2) y del ecocardiograma Doppler (como el cambio del área fraccional y diámetro de la aurícula derecha), no demostraron asociación estadística. (<xref ref-type="bibr" rid="B5">5</xref>)</p>
		<p>Es un estudio muy interesante, que de aplicarse en un número mayor de pacientes nos permitiría valorar otras asociaciones significativas del ecocardiograma con</p>
		<p>el TECP, y poder aplicarlos en la práctica clínica diaria.</p>
	</body>
	<back>
		<ref-list>
			<title>BIBLIOGRAFÍA</title>
			<ref id="B1">
				<label>1</label>
				<mixed-citation>HumbertM, KovacsG, HoeperMM, BadagliaccaR, BergerRM, BridaM; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022;3:3618-731. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/eurheartj/ehac237">https://doi.org/10.1093/eurheartj/ehac237</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Humbert</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Kovacs</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Hoeper</surname>
							<given-names>MM</given-names>
						</name>
						<name>
							<surname>Badagliacca</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Berger</surname>
							<given-names>RM</given-names>
						</name>
						<name>
							<surname>Brida</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<person-group person-group-type="author">
						<collab>ESC/ERS Scientific Document Group</collab>
					</person-group>
					<article-title>2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension</article-title>
					<source>Eur Heart J</source>
					<year>2022</year>
					<volume>3</volume>
					<fpage>3618</fpage>
					<lpage>3731</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/eurheartj/ehac237">https://doi.org/10.1093/eurheartj/ehac237</ext-link>
				</element-citation>
			</ref>
			<ref id="B2">
				<label>2</label>
				<mixed-citation>BenzaRL, KanwarMK, RainaA, ScottJV, ZhaoCL, SelejM. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. Chest 2021;159:337-46. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.chest.2020.08.2069">https://doi.org/10.1016/j.chest.2020.08.2069</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Benza</surname>
							<given-names>RL</given-names>
						</name>
						<name>
							<surname>Kanwar</surname>
							<given-names>MK</given-names>
						</name>
						<name>
							<surname>Raina</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Scott</surname>
							<given-names>JV</given-names>
						</name>
						<name>
							<surname>Zhao</surname>
							<given-names>CL</given-names>
						</name>
						<name>
							<surname>Selej</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension</article-title>
					<source>Chest</source>
					<year>2021</year>
					<volume>159</volume>
					<fpage>337</fpage>
					<lpage>346</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.chest.2020.08.2069">https://doi.org/10.1016/j.chest.2020.08.2069</ext-link>
				</element-citation>
			</ref>
			<ref id="B3">
				<label>3</label>
				<mixed-citation>ShermanAE, SaggarR. Cardiopulmonary Exercise Testing in Pulmonary Arterial Hypertension. Heart Fail Clin 2023;19:35-43. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.hfc.2022.08.015">https://doi.org/10.1016/j.hfc.2022.08.015</ext-link>.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Sherman</surname>
							<given-names>AE</given-names>
						</name>
						<name>
							<surname>Saggar</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>Cardiopulmonary Exercise Testing in Pulmonary Arterial Hypertension</article-title>
					<source>Heart Fail Clin</source>
					<year>2023</year>
					<volume>19</volume>
					<fpage>35</fpage>
					<lpage>43</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.hfc.2022.08.015">https://doi.org/10.1016/j.hfc.2022.08.015</ext-link>
				</element-citation>
			</ref>
			<ref id="B4">
				<label>4</label>
				<mixed-citation>DmytriievK, SticklandM, WeatheraldJ. Cardiopulmonary Exercise Testing in Pulmonary Hypertension. Heart Fail Clin 2025;21:51-61. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.hfc.2024.05.002">https://doi.org/10.1016/j.hfc.2024.05.002</ext-link>.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Dmytriiev</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Stickland</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Weatherald</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Cardiopulmonary Exercise Testing in Pulmonary Hypertension</article-title>
					<source>Heart Fail Clin</source>
					<year>2025</year>
					<volume>21</volume>
					<fpage>51</fpage>
					<lpage>61</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.hfc.2024.05.002">https://doi.org/10.1016/j.hfc.2024.05.002</ext-link>
				</element-citation>
			</ref>
			<ref id="B5">
				<label>5</label>
				<mixed-citation>D' AmelioN, KaplanP, LagoM, SoutoG, AmorM, BruzzeseM. Ergoespirometría en pacientes con Hipertensión Pulmonar precapilar precapilar: evaluación del valor predictivo de variables ecocardiográficas. Rev Argent Cardiol 2025; 93:83-5. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7775/rac.es.v93.i1.20853">https://doi.org/10.7775/rac.es.v93.i1.20853</ext-link> .</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>D' Amelio</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Kaplan</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Lago</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Souto</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Amor</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Bruzzese</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Ergoespirometría en pacientes con Hipertensión Pulmonar precapilar precapilar: evaluación del valor predictivo de variables ecocardiográficas</article-title>
					<source>Rev Argent Cardiol</source>
					<year>2025</year>
					<volume>93</volume>
					<fpage>83</fpage>
					<lpage>85</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7775/rac.es.v93.i1.20853">https://doi.org/10.7775/rac.es.v93.i1.20853</ext-link>
				</element-citation>
			</ref>
		</ref-list>
		<fn-group>
			<fn fn-type="other" id="fn0">
				<label>0</label>
				<p>Miembro Titular de la Sociedad Argentina de Cardiología</p>
			</fn>
		</fn-group>
	</back>
	<!--<sub-article article-type="reply" id="s1" xml:lang="es">
		<front-stub>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Articles</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>RESPUESTA DE LOS AUTORES</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<name>
						<surname>D´Amelio</surname>
						<given-names>Nicolás</given-names>
					</name>
				</contrib>
			</contrib-group>
		</front-stub>
		<body>
			<p>Quisiera agradecer la carta de la Dra. Sorasio en donde hace un resumen detallado y muy claro del rol que ocupa cada variable analizada en la estratificación de riesgo de los pacientes con HTP. A modo de respuesta quisiera resaltar como fortaleza del trabajo realizado que la correlación encontrada entre</p>
			<p>TAPSE/PSAP y VO2 pico fue en pacientes crónicos, tratados según el riesgo establecido para cada uno de ellos y sin modificar la terapéutica en los últimos dos meses, por lo que la posibilidad de utilizar una variable del ecocardiograma como subrogante del TECP podría tener aplicación en la estratificación de riesgo de dichos pacientes en seguimiento.</p>
			<sig-block>
				<sig>Nicolás D´Amelio</sig>
			</sig-block>
		</body>
	</sub-article>
	<sub-article article-type="translation" id="s2" xml:lang="en">
		<front-stub>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>LETTERS FROM READERS</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Correlation of Ergospirometry with Echocardiography in Pulmonary Arterial Hypertension</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-8508-4482</contrib-id>
					<name>
						<surname>SORASIO</surname>
						<given-names>GUILLERMINA</given-names>
					</name>
					<xref ref-type="aff" rid="aff4"><sup>1</sup></xref>
					<xref ref-type="aff" rid="aff5"><sup>2</sup></xref>
					<xref ref-type="aff" rid="aff6"><sup>3</sup></xref>
					<xref ref-type="fn" rid="fn0"><sup>MTSAC</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff4">
				<label>1</label>
				<institution content-type="original">Responsible physician for Heart Failure and Pulmonary Hypertension at Hospital Rivadavia,</institution>
				<institution content-type="orgname">Hospital Rivadavia</institution>
			</aff>
			<aff id="aff5">
				<label>2</label>
				<institution content-type="original">Staff physician of Pulmonary Hypertension at Trinidad Ramos Mejía</institution>
				<institution content-type="orgname">Trinidad Ramos Mejía</institution>
			</aff>
			<aff id="aff6">
				<label>3</label>
				<institution content-type="original">Staff of network of BASA health centers.</institution>
				<institution content-type="orgname">network of BASA health centers</institution>
			</aff>
			<author-notes>
				<corresp id="c2">
					<label>Correspondence:</label> Guillermina Sorasio. Las Heras 2670. Ciudad de Buenos Aires Correo electrónico: guillerminasorasio@gmail.com</corresp>
				<fn fn-type="conflict" id="fn3">
					<label>Conflicts of interest</label>
					<p> None declared. (See authors conflicts of interest forms on the website).</p>
				</fn>
				<fn fn-type="conflict" id="fn4">
					<label>Ethical considerations</label>
					<p> Not applicable</p>
				</fn>
			</author-notes>
		</front-stub>
		<body>
			<p>Pulmonary arterial hypertension (PAH) is a heterogeneous, chronic and progressive entity that leads to remodeling of the pulmonary arterioles with subsequent increase in pulmonary vascular resistance (PVR) and right ventricular function impairment, the main predictor of mortality (<xref ref-type="bibr" rid="B6">1</xref>).</p>
			<p>It is essential to perform adequate baseline risk and follow-up stratification in these patients in order to initiate early treatment based on known risk scores. (<xref ref-type="bibr" rid="B7">2</xref>)</p>
			<p>Although the 6-minute walk test is the most accessible and simple technique to assess functional capacity, it has certain limitations such as the influence of sex, age, height, weight, comorbidities and learning curve, among others. For this reason, ergospirometry or cardiopulmonary exercise test (CPET) is the ideal method to determine exercise limitation, though it is not very accessible and expensive. (<xref ref-type="bibr" rid="B8">3</xref>)</p>
			<p>As mentioned above, stratifying patients with PAH at baseline and during follow-up is a priority, and CPET with variables such as peak oxygen consumption (peak VO<sub>2</sub> ) and ventilation to carbon dioxide production ratio (VE/VCO<sub>2</sub>) is an important part of it. (<xref ref-type="bibr" rid="B9">4</xref>)</p>
			<p>Among the echocardiographic variables, the relationship between the tricuspid annular plane systolic excursion distance (TAPSE) and pulmonary artery systolic pressure (PASP) as a surrogate of ventricular arterial coupling, and the reduction of the stroke volume index (SVI) have been associated with poor prognosis in PAH.</p>
			<p>The prognostic association between CPET variables, mainly VE/VCO<sub>2</sub> ratio and VO<sub>2</sub>, and echocardiographic variables, as the TAPSE/PSAP ratio, is not well established.</p>
			<p>The study by D' Amelio et al. evaluated the predictive ability of echocardiographic right ventricular function parameters in relation to exercise capacity, and compared CPET with the echocardiogram. Seven patients were included, most of them with PAH and chronic thromboembolic pulmonary hypertension (CTEPH). A statistically significant correlation was observed in the linear regression between TAPSE/PSAP ratio and peak VO<sub>2</sub>. Although the number of patients is limited for decision making, it is an interesting hypothesis when it comes to correlating the more accessible echocardiogram with CPET, thus allowing the assessment of the functional capacity of patients with PAH, which is an important prognostic parameter. The rest of the CPET variables such as the VE/VCO<sub>2</sub> slope and Doppler echocardiogram variables, as fractional area and right atrial diameter change did not show statistical association. (<xref ref-type="bibr" rid="B10">5</xref>)</p>
			<p>This is a very interesting study that when applied to a larger number of patients will allow us to evaluate other significant associations of echocardiographic variables with CPET and enable their application to daily clinical practice.</p>
		</body>
		<back>
			<ref-list>
				<title>REFERENCES</title>
				<ref id="B6">
					<label>1</label>
					<mixed-citation>1. HumbertM, KovacsG, HoeperMM, BadagliaccaR, BergerRM, BridaM; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022;3:3618-731. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/eurheartj/ehac237">https://doi.org/10.1093/eurheartj/ehac237</ext-link>
					</mixed-citation>
					<element-citation publication-type="journal">
						<person-group person-group-type="author">
							<name>
								<surname>Humbert</surname>
								<given-names>M</given-names>
							</name>
							<name>
								<surname>Kovacs</surname>
								<given-names>G</given-names>
							</name>
							<name>
								<surname>Hoeper</surname>
								<given-names>MM</given-names>
							</name>
							<name>
								<surname>Badagliacca</surname>
								<given-names>R</given-names>
							</name>
							<name>
								<surname>Berger</surname>
								<given-names>RM</given-names>
							</name>
							<name>
								<surname>Brida</surname>
								<given-names>M</given-names>
							</name>
						</person-group>
						<person-group person-group-type="author">
							<collab>ESC/ERS Scientific Document Group</collab>
						</person-group>
						<article-title>2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension</article-title>
						<source>Eur Heart J</source>
						<year>2022</year>
						<volume>3</volume>
						<fpage>3618</fpage>
						<lpage>3731</lpage>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/eurheartj/ehac237">https://doi.org/10.1093/eurheartj/ehac237</ext-link>
					</element-citation>
				</ref>
				<ref id="B7">
					<label>2</label>
					<mixed-citation>2. BenzaRL, KanwarMK, RainaA, ScottJV, ZhaoCL, SelejM. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. Chest 2021;159:337-46. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.chest.2020.08.2069">https://doi.org/10.1016/j.chest.2020.08.2069</ext-link>
					</mixed-citation>
					<element-citation publication-type="journal">
						<person-group person-group-type="author">
							<name>
								<surname>Benza</surname>
								<given-names>RL</given-names>
							</name>
							<name>
								<surname>Kanwar</surname>
								<given-names>MK</given-names>
							</name>
							<name>
								<surname>Raina</surname>
								<given-names>A</given-names>
							</name>
							<name>
								<surname>Scott</surname>
								<given-names>JV</given-names>
							</name>
							<name>
								<surname>Zhao</surname>
								<given-names>CL</given-names>
							</name>
							<name>
								<surname>Selej</surname>
								<given-names>M</given-names>
							</name>
						</person-group>
						<article-title>Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension</article-title>
						<source>Chest</source>
						<year>2021</year>
						<volume>159</volume>
						<fpage>337</fpage>
						<lpage>346</lpage>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.chest.2020.08.2069">https://doi.org/10.1016/j.chest.2020.08.2069</ext-link>
					</element-citation>
				</ref>
				<ref id="B8">
					<label>3</label>
					<mixed-citation>3. ShermanAE, SaggarR. Cardiopulmonary Exercise Testing in Pulmonary Arterial Hypertension. Heart Fail Clin 2023;19:35-43. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.hfc.2022.08.015">https://doi.org/10.1016/j.hfc.2022.08.015</ext-link>.</mixed-citation>
					<element-citation publication-type="journal">
						<person-group person-group-type="author">
							<name>
								<surname>Sherman</surname>
								<given-names>AE</given-names>
							</name>
							<name>
								<surname>Saggar</surname>
								<given-names>R</given-names>
							</name>
						</person-group>
						<article-title>Cardiopulmonary Exercise Testing in Pulmonary Arterial Hypertension</article-title>
						<source>Heart Fail Clin</source>
						<year>2023</year>
						<volume>19</volume>
						<fpage>35</fpage>
						<lpage>43</lpage>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.hfc.2022.08.015">https://doi.org/10.1016/j.hfc.2022.08.015</ext-link>
					</element-citation>
				</ref>
				<ref id="B9">
					<label>4</label>
					<mixed-citation>4. DmytriievK, SticklandM, WeatheraldJ. Cardiopulmonary Exercise Testing in Pulmonary Hypertension. Heart Fail Clin 2025;21:51-61. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.hfc.2024.05.002">https://doi.org/10.1016/j.hfc.2024.05.002</ext-link>.</mixed-citation>
					<element-citation publication-type="journal">
						<person-group person-group-type="author">
							<name>
								<surname>Dmytriiev</surname>
								<given-names>K</given-names>
							</name>
							<name>
								<surname>Stickland</surname>
								<given-names>M</given-names>
							</name>
							<name>
								<surname>Weatherald</surname>
								<given-names>J</given-names>
							</name>
						</person-group>
						<article-title>Cardiopulmonary Exercise Testing in Pulmonary Hypertension</article-title>
						<source>Heart Fail Clin</source>
						<year>2025</year>
						<volume>21</volume>
						<fpage>51</fpage>
						<lpage>61</lpage>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.hfc.2024.05.002">https://doi.org/10.1016/j.hfc.2024.05.002</ext-link>
					</element-citation>
				</ref>
				<ref id="B10">
					<label>5</label>
					<mixed-citation>5. D' AmelioN, KaplanP, LagoM, SoutoG, AmorM, BruzzeseM. Ergospirometry in Patients with Precapillary Pulmonary Hypertension: Evaluation of the Predictive Value of Echocardiographic Variables. Rev Argent Cardiol 2025; 93:83-5. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7775/rac.v93.i1.20853">https://doi.org/10.7775/rac.v93.i1.20853</ext-link> .</mixed-citation>
					<element-citation publication-type="journal">
						<person-group person-group-type="author">
							<name>
								<surname>D' Amelio</surname>
								<given-names>N</given-names>
							</name>
							<name>
								<surname>Kaplan</surname>
								<given-names>P</given-names>
							</name>
							<name>
								<surname>Lago</surname>
								<given-names>M</given-names>
							</name>
							<name>
								<surname>Souto</surname>
								<given-names>G</given-names>
							</name>
							<name>
								<surname>Amor</surname>
								<given-names>M</given-names>
							</name>
							<name>
								<surname>Bruzzese</surname>
								<given-names>M</given-names>
							</name>
						</person-group>
						<article-title>Ergospirometry in Patients with Precapillary Pulmonary Hypertension: Evaluation of the Predictive Value of Echocardiographic Variables</article-title>
						<source>Rev Argent Cardiol</source>
						<year>2025</year>
						<volume>93</volume>
						<fpage>83</fpage>
						<lpage>85</lpage>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7775/rac.v93.i1.20853">https://doi.org/10.7775/rac.v93.i1.20853</ext-link>
					</element-citation>
				</ref>
			</ref-list>
		</back>
		<sub-article article-type="reply" id="s3" xml:lang="en">
			<front-stub>
				<article-categories>
					<subj-group subj-group-type="heading">
						<subject>Articles</subject>
					</subj-group>
				</article-categories>
				<title-group>
					<article-title>AUTHORS’ REPLY</article-title>
				</title-group>
				<contrib-group>
					<contrib contrib-type="author">
						<name>
							<surname>D´Amelio</surname>
							<given-names>Nicolás</given-names>
						</name>
					</contrib>
				</contrib-group>
			</front-stub>
			<body>
				<p>I would like to thank Dr. Sorasio for her detailed and clear summary of the role played by each variable analyzed in the risk stratification of patients with PH. In response, I would like to highlight as a strength of the study that we found the correlation between TAPSE/ sPAP and peak VO<sub>2</sub> in chronic patients treated according to the risk established for each one, and without modifying the therapeutic the last two months. So, the possibility of using an echocardiogram variable as a surrogate for CPET could have application in the risk stratification of those patients in follow-up.</p>
				<sig-block>
					<sig>Nicolás D´Amelio</sig>
				</sig-block>
			</body>
		</sub-article>
	</sub-article>-->
</article>